The healthcare industry in India is at a watershed moment. A significant amount of credit goes to the advancements in the pharmaceutical and diagnostics industries. The pharmaceutical industry has been under immense pressure ever since the first case of COVID-19 was reported. However, one of the silver linings of the pandemic was that it triggered more remarkable ways to research and develop vaccines. Eventually, the pharmaceutical industry came out all guns blazing, developing covid-19 vaccines in record time. In the process, the pandemic forced the implementation of many technologies and innovations, which were just a part of the conversation otherwise. COVID-19 made the

BioTech industry think about the similar healthcare catastrophes ahead of us and how to be prepared to face such predicaments, hence the increasing focus on approaches like Immuno modulatory therapy.

On the other hand catering to a whopping 140 crore population, the diagnostic industry in India is highly unorganized,constituting a high degree of fragmentation with over 1,00,000 labs. While the vast nature of the market calls for unique, India centric business models, the healthcare industry becoming more evidence-based and clinical investigations centric has ensured that the diagnostics organizations have no room for anything less than world class quality. This has inevitably polished out high octane competitiveness among large diagnostic chains and startups alike. In the aftermath, there has been a phenomenal rise in the use of technology, which has become an integral part of the sectors efforts to improve customer experience and support clinical decisions. A case in point is the Direct to (Patient's) Home healthcare model taking diagnostics and therapies to the patient's home is something the pharmaceutical industry has been talking about for quite some time. We are here with a few interesting stories from the healthcare domain.